Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Accumulated Expenses (2016 - 2025)

Fennec Pharmaceuticals (FENC) has disclosed Accumulated Expenses for 15 consecutive years, with $3.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Accumulated Expenses rose 11.71% year-over-year to $3.7 million, compared with a TTM value of $3.7 million through Sep 2025, up 11.71%, and an annual FY2024 reading of $3.4 million, down 8.68% over the prior year.
  • Accumulated Expenses was $3.7 million for Q3 2025 at Fennec Pharmaceuticals, up from $2.2 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $3.8 million in Q4 2023 and bottomed at $171000.0 in Q2 2021.
  • Average Accumulated Expenses over 5 years is $1.7 million, with a median of $1.3 million recorded in 2023.
  • Peak annual rise in Accumulated Expenses hit 327.86% in 2021, while the deepest fall reached 60.69% in 2021.
  • Year by year, Accumulated Expenses stood at $860000.0 in 2021, then skyrocketed by 158.02% to $2.2 million in 2022, then surged by 69.18% to $3.8 million in 2023, then fell by 8.68% to $3.4 million in 2024, then increased by 7.96% to $3.7 million in 2025.
  • Business Quant data shows Accumulated Expenses for FENC at $3.7 million in Q3 2025, $2.2 million in Q2 2025, and $2.8 million in Q1 2025.